EUVIMEDEUVIMED entdecken
Crossref

LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models

Kai Yang, Yaolong Zhou, Jie Cui, Weifeng Tang, Yujun Chen, Xiqun Chen

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Kai Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Asthma, Disease Models, Animal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Directorate for Geosciences, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a complex inflammatory airway disease that arises from the interplay between genetic predisposition and environmental influences. Leucine-rich repeat kinase 2 (LRRK2), a gene commonly associated with Parkinson's disease, has recently gained attention for its role in immune regulation and inflammation beyond the brain. However, its involvement in asthma has not yet been reported. In this study, we used LRRK2 G2019S transgenic mice and LRRK2 knockout mice to establish asthmatic models to explore LRRK2 impact on asthma. We found that LRRK2 G2019S transgenic mice showed exacerbated airway hyperresponsiveness (AHR) and airway inflammation in asthma mouse models induced by house dust mite. RNA sequencing data unveiled that the LRRK2 G2019S mutation enhanced immune response pathways, including NOD-like receptor, cellular response to interferon β and activation of innate immune response signaling. Conversely, LRRK2 deficiency attenuated AHR and airway inflammation in the same asthma models. Our study offers new insights into the role of LRRK2 in allergic inflammation and highlights its potential as a therapeutic target for asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2AsthmaDisease Models, AnimalAnimalsMiceMice, TransgenicMice, KnockoutMice, Inbred C57BLImmunity, InnateMutationPyroglyphidaeSignal TransductionInflammation

Stichwörter der Autor:innen

Airway inflammationAsthmaG2019S transgenicImmune response pathwaysKnockoutLRRK2

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Lrrk2 protein, mouse

Autor:innen und Institutionen

  • Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China; Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electro…
  • Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: chen_xiqun@fudan.edu.cn.

Förderung

  • Directorate for Geosciences
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Yang, K., Zhou, Y., Cui, J., Tang, W., Chen, Y., & Chen, X. (2024). LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150593

Vancouver

Yang K, Zhou Y, Cui J, Tang W, Chen Y, Chen X. LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150593

BibTeX
@article{Yang2024,
  author = {Yang, Kai and Zhou, Yaolong and Cui, Jie and Tang, Weifeng and Chen, Yujun and Chen, Xiqun},
  title = {LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150593}
}
Kostenlos starten →